Valuation: Vaccinex, Inc.

Market Cap 2.88M 2.52M 2.32M 2.14M 4.03M 277M 4.12M 27.75M 10.91M 136M 10.81M 10.57M 467M P/E 2023
-0.21x
P/E 2024 -0.11x
Enterprise Value 1.8M 1.57M 1.45M 1.34M 2.52M 173M 2.57M 17.32M 6.81M 84.74M 6.75M 6.6M 292M EV / Sales 2023
12.3x
EV / Sales 2024 2.56x
Free-Float
88.59%
Yield 2023 *
-
Yield 2024 -
1 day-0.86%
1 week-10.85%
Current month+12.75%
1 month+3.60%
3 months+15.00%
6 months-14.81%
Current year+6.93%
1 week 1.12
Extreme 1.12
1.16
1 month 0.77
Extreme 0.7701
1.29
Current year 0.34
Extreme 0.34
1.5
1 year 0.31
Extreme 0.31
1.5
3 years 0.25
Extreme 0.2521
65.98
5 years 0.25
Extreme 0.2521
560.7
10 years 0.25
Extreme 0.2521
2,568.3
Manager TitleAgeSince
Chief Executive Officer 80 2001-03-31
Director of Finance/CFO 54 2024-03-13
Chief Operating Officer 54 2021-05-10
Director TitleAgeSince
Director/Board Member 80 2001-03-31
Chairman 79 2001-03-31
Director/Board Member 69 2015-01-31
Date Insider Type Main position Quantity % Market Cap.
11/14/24 Other

Founder

46,153 1.6512%
11/14/24 Other

Chairman

0 0%
11/14/24
Friedberg Mercantile Group Ltd. /Friedberg Family/
OtherCompany 615,402 22.0164%
Change 5-day change 1-year change 3-year change Capi.($)
-0.86%-10.85%+26.37%-98.22% 3.08M
-0.27%-1.37%+55.11%+56.47% 53.83B
-7.17%-4.39%+42.72%+73.70% 52.1B
+0.80%-6.31%+5.62%+413.12% 23.48B
-0.09%-0.01%-16.85%-16.17% 23.13B
+3.46%+2.52%+36.64%-5.41% 19.36B
+0.23%-1.73%+34.42%-32.45% 17.56B
-5.16%-7.00%+168.44%+291.24% 15.2B
+3.62%0.00%+33.47%+643.91% 14.83B
+0.43%-1.03%+25.75%+186.18% 14.06B
Average -0.52%-3.45%+41.17%+151.24% 23.36B
Weighted average by Cap. -1.40%-2.36%+41.39%+137.54%

Financials

2023 2024
Net sales 570K 498K 460K 424K 799K 54.89M 816K 5.49M 2.16M 26.88M 2.14M 2.09M 92.55M 601K 525K 485K 447K 842K 57.88M 861K 5.79M 2.28M 28.35M 2.26M 2.21M 97.58M
Net income -20.25M -17.7M -16.33M -15.05M -28.37M -1.95B -29M -195M -76.77M -955M -76.05M -74.38M -3.29B -18.63M -16.28M -15.03M -13.85M -26.11M -1.79B -26.69M -180M -70.64M -879M -69.98M -68.44M -3.03B
Net Debt -1.29M -1.13M -1.04M -957K -1.8M -124M -1.84M -12.41M -4.88M -60.75M -4.84M -4.73M -209M -1.08M -946K -873K -804K -1.52M -104M -1.55M -10.43M -4.1M -51.03M -4.06M -3.97M -176M
Logo Vaccinex, Inc.
Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimer’s disease, head and neck, pancreatic and breast cancer. Its platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. Its SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including neuroinflammatory and neurodegenerative diseases and cancer. It also discovered VX5 using its ActivMAb platform. VX5 is a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, and is in preclinical development for the treatment of autoimmune disorders.
Employees
25
Date Price Change Volume
26-07-17 US$1.150 -0.86% 561
26-07-14 US$1.160 -10.08% 658
  1. Stock Market
  2. Stocks
  3. VCNX Stock